Zhang Qian, Guo Jianming, Dai Guoliang, Li Jianping, Zhu Lijing, He Shufen, Zong Yang, Tang Zhishu, Zhao Buchang, Ju Wenzheng, Duan Jinao
The Department of Pharmacy, The Affiliated Hospital of Nanjing University of Chinese Medicine, No. 155, Hanzhong Road, Nanjing, 210029, People's Republic of China.
Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources, Jiangsu Key Laboratory for High Technology Research of TCM Formulae, National and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine, Nanjing University of Chinese Medicine, No. 138, Xianlin Avenue, Nanjing, 210046, People's Republic of China.
Eur J Drug Metab Pharmacokinet. 2019 Aug;44(4):505-517. doi: 10.1007/s13318-018-0530-6.
Danhong injection is the most commonly prescribed adjuvant drug applied for the treatment of cardiovascular and cerebrovascular diseases in China. Ceftriaxone is usually prescribed along with Danhong injection to elderly patients with complications. However, the pharmacokinetic interactions between these two medications have not been investigated. The aim of this study was to investigate whether Danhong injection influences the pharmacokinetic profile of ceftriaxone in old rats when these two medications are used in combination.
The animal experiment protocol was designed according to the clinical data. Ten-month-old male Sprague-Dawley (SD) rats were dosed with ceftriaxone through intravenous administration for 1 or 7 days in the presence or absence of Danhong injection. The combinations were divided into 1-day, 7-day, and 14-day combined-treatment groups in which Danhong injection was administered for 1, 7, or 14 days and ceftriaxone was given for 1, 7, or 7 days, respectively. The plasma concentration of ceftriaxone was determined by ultrahigh performance liquid chromatography coupled with triple-quadrupole mass spectrometry (UHPLC-TQ-MS) on a BEH C18 column with a mobile phase consisting of acetonitrile and 0.4% formic acid-water. The chromatographic method was validated and found to be simple, rapid, and stable.
Danhong injection significantly increased the plasma clearance of and decreased systemic exposure to ceftriaxone. In the 1-day combined-treatment group, the plasma clearance of ceftriaxone increased by 52.69%, and the area under the concentration-time curve (AUC) of ceftriaxone was decreased by 32.54% (P < 0.01). In the 7-day combined-treatment group, the rate of plasma clearance increased by 52.49% and the area under the concentration-time curve decreased by 31.15% (P < 0.01). For the 14-day combined-treatment group, the plasma clearance of ceftriaxone increased by 26.73%, and the area under the concentration-time curve decreased by 21.44% (P < 0.05).
In old male rats, systemic exposure to ceftriaxone decreased when used concomitantly with Danhong injection, which may be because Danhong injection increased the plasma clearance of ceftriaxone. Further investigations should be carried out to clarify the mechanism for the influence of Danhong injection on the pharmacokinetics of ceftriaxone.
丹红注射液是中国治疗心脑血管疾病最常用的辅助药物。头孢曲松通常与丹红注射液联合用于患有并发症的老年患者。然而,这两种药物之间的药代动力学相互作用尚未得到研究。本研究的目的是探讨当这两种药物联合使用时,丹红注射液是否会影响老年大鼠体内头孢曲松的药代动力学特征。
根据临床数据设计动物实验方案。将10月龄雄性Sprague-Dawley(SD)大鼠在有或无丹红注射液的情况下静脉注射头孢曲松1或7天。联合用药组分为1天、7天和14天联合治疗组,分别给予丹红注射液1、7或14天,头孢曲松分别给予1、7或7天。采用超高效液相色谱-三重四极杆质谱联用(UHPLC-TQ-MS)法,在BEH C18柱上,以乙腈和0.4%甲酸-水为流动相,测定头孢曲松的血浆浓度。该色谱方法经过验证,结果表明其简便、快速且稳定。
丹红注射液显著增加了头孢曲松的血浆清除率并降低了其全身暴露量。在1天联合治疗组中,头孢曲松的血浆清除率增加了52.69%,头孢曲松的浓度-时间曲线下面积(AUC)降低了32.54%(P<0.01)。在7天联合治疗组中,血浆清除率增加了52.49%,浓度-时间曲线下面积降低了31.15%(P<0.01)。在14天联合治疗组中,头孢曲松的血浆清除率增加了26.73%,浓度-时间曲线下面积降低了21.44%(P<0.05)。
在老年雄性大鼠中,与丹红注射液联合使用时,头孢曲松的全身暴露量降低,这可能是因为丹红注射液增加了头孢曲松的血浆清除率。应进一步开展研究以阐明丹红注射液影响头孢曲松药代动力学的机制。